拉米夫定、苦参素治疗慢性乙型肝炎早期肝硬化临床观察

目的探讨拉米夫定联合苦参素治疗慢性乙型肝炎合并早期肝硬化临床效果。方法选择我院2007～2010年收治的慢性乙型肝炎合并早期肝硬化患者82例，随机分为观察组和对照组各41例。观察组给予拉米夫定和苦参素联合治疗，对照组给予拉米夫定治疗，比较两组患者治疗前后的乙肝病毒指标、肝功能指标和肝纤维化指标。结果观察组治疗后在肝功能生化指标、肝纤维化指标方面显著好于对照组（P〈0．05），观察组HBV—DNA转阴率、HBeAg转阴率和血清HBeAg转换率分别为87．8％、57．1％和38．1％，显著好于对照组（P〈0．05）。结论拉米夫定联合苦参素治疗慢性乙型肝炎早期肝硬化疗效显著，二者相辅相成，加速抑制乙肝病毒复制，改善肝功能，缓解病情，从而改善患者生活质量和延长存活时间。

Study of clinical effect of lamivudine combined with matrine in patients with HBV-related early liver cirrhosis

Objective To investigate the clinical effect of lamivudine combined with matrine in patients with HBV-related early liver cirrhosis.Methods Eighty-two patients with HBV-related early liver cirrhosis were selected and divided into two groups with 41 cases for each,patients in observation group were given lamivudine and matrine,and other patients in control group were given lamivudine.Liver function,indicators of HBV and liver fibrosis were compared after treatment for 48 weeks.Results The indicators of liver function and liver fibrosis of observation group were significantly better than those of control group(P < 0.05);the negative rates of HBV-DNA and HBeAg of observation group were 87.8% and 57.1% respectively(P < 0.05).Conclusion The method of lamivudine combined with matrine in treating HBV-related early liver cirrhosis has a good effect and deserves to clinical application.